DOCSLIB.ORG

Erythropoietin Stimulates Gabaergic Maturation in the Mouse Hippocampus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Erythropoietin Stimulates Gabaergic Maturation in the Mouse Hippocampus Research Article: New Research | Development Erythropoietin Stimulates GABAergic Maturation in the Mouse Hippocampus https://doi.org/10.1523/ENEURO.0006-21.2021 Cite as: eNeuro 2021; 10.1523/ENEURO.0006-21.2021 Received: 7 January 2021 Accepted: 9 January 2021 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2021 Khalid et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. 1 Erythropoietin Stimulates GABAergic Maturation in the Mouse Hippocampus 2 Abbreviated Title: EPO and hippocampal GABAergic maturation 1,3,+ 1,+ 2 1,2 3 Kasifa Khalid , Julia Frei , Mostafa A. Aboouf , Christina Koester-Hegmann , Max 4 Gassmann2, Jean-Marc Fritschy1,3 and Edith M. Schneider Gasser1,2,3 5 1Institute of Pharmacology and Toxicology, Neuroprotection Group, University of Zurich, 6 Winterthurerstrasse 190, 8057 Zurich, Switzerland 7 2Institute of Veterinary Physiology, Vetsuisse Faculty, and Zurich Center for Integrative 8 Human Physiology, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland 9 3Neuroscience Centre Zurich, University of Zurich and ETH Zurich, 8057 Zurich, Switzerland 10 +Equal contribution 11 Author contributions: EMSG designed research; KK, JF, MAA, CK-H, and EMSG 12 performed research and analyzed data; MG provided transgenic Tg21 mice and expertise 13 with those; EMSG and J-MF wrote the manuscript. 14 Correspondence should be addressed to: [email protected] 15 Number of figures: 8 Number of words for abstract: 203 16 Tables: 1 Number of words significant statement: 98 17 Number of words introduction: 830 18 Number of Words discussion: 1621 19 Acknowledgements: We thank Prof. Christian Grimm for scientific feedback; Dr. Lena Rubi 20 and Mr. Mohammad Hleihil for their support with electrophysiology; Dr. Tatjana Haenggi for 21 genotyping the animals; Fabio Valeri for his support with statistics; and Barbara Ellis, Dr. 22 Christina Boyle and Dr. Robert Ganley for proofreading this manuscript. 23 Conflict of interests: The authors declare no conflict of interests. 24 Funding sources: This work was supported by University of Zürich and Swiss National 25 Science Foundation MHV Grant PMPDP3_145480 to E.M.S.G. and the Baugenossenschaft 26 Zurlinden. 1 27 Abstract 28 Several neurodevelopmental disabilities are strongly associated with alterations in 29 GABAergic transmission, and therapies to stimulate its normal development are lacking. 30 Erythropoietin (EPO) is clinically used in neonatology to mitigate acute brain injury, and to 31 stimulate neuronal maturation. Yet it remains unclear whether EPO can stimulate maturation 32 of the GABAergic system. Here, with the use of a transgenic mouse line that constitutively 33 overexpresses neuronal EPO (Tg21), we show that EPO stimulates postnatal GABAergic 34 maturation in the hippocampus. We show an increase in hippocampal GABA- 35 immunoreactive neurons, and postnatal elevation of interneurons expressing parvalbumin 36 (PV), somatostatin (SST) and neuropeptide Y (NPY). Analysis of perineuronal net formation 37 and innervation of glutamatergic terminals onto PV+ cells, shows to be enhanced early in 38 postnatal development. Additionally, an increase in GABAAergic synapse density and 39 inhibitory postsynaptic currents (IPSCs) in CA1 pyramidal cells from Tg21 mice is observed. 40 Detection of erythropoietin receptor (EPOR) mRNA was observed to be restricted to 41 glutamatergic pyramidal cells and increased in Tg21 mice at postnatal day 7, along with 42 reduced apoptosis. Our findings show that EPO can stimulate postnatal GABAergic 43 maturation in the hippocampus, by increasing neuronal survival, modulating critical plasticity 44 periods, and increasing synaptic transmission. Our data supports EPO’s clinical use to 45 balance GABAergic dysfunction. 46 Significance Statement 47 Using a mouse model that overexpresses recombinant human EPO in the CNS, we 48 observed stimulation of the postnatal maturation of GABAergic transmission in the 49 hippocampus, notably accelerated maturation of PV+ interneurons, enhanced glutamatergic 50 inputs onto these interneurons, and enhanced inhibitory postsynaptic currents (IPSCs) onto 51 pyramidal cells. We show that EPORs are expressed on pyramidal cells, therefore the impact 52 of EPO on GABAergic maturation is likely to be indirect. Our data show that EPO can 2 53 modulate hippocampal network maturation and support ongoing trials of the use of EPO in 54 clinical neonatology to stimulate neuronal maturation after perinatal brain injury. 55 Introduction 56 Perinatal brain injury (PBI) might lead to psychiatric disorders associated with alterations in 57 GABAergic transmission (Marin 2012, Cunha-Rodrigues, Balduci et al. 2018, Lacaille, 58 Vacher et al. 2019). A significant reduction of several markers of GABAergic transmission, 59 including glutamic acid decarboxylase (GAD), GABA, GABAA receptors (GABAARs), and 60 perturbed parvalbumin (PV) and somatostatin (SST) expression in cortical interneurons, 61 have been reported in the neonatal brain after injury (Robinson, Li et al. 2006, Komitova, 62 Xenos et al. 2013). In addition, postmortem samples from human preterm infants with brain 63 injury, as well as the hippocampus of rat models of prematurity, showed reduced potassium- 64 chloride co-transporter 2 (KCC2) expression (Jantzie, Getsy et al. 2014). Perturbations of the 65 GABAergic system in PBI might disrupt the excitatory/inhibitory balance and lead to long- 66 lasting deficits in brain function (Komitova, Xenos et al. 2013). Therefore, there is an urgent 67 need for new therapeutic strategies protecting the GABAergic system in clinical neonatology. 68 Erythropoietin (EPO), the erythropoietic hormone (Farrell and Lee 2004). is a leading therapy 69 in neonatology as a neuroprotective agent (Juul, Mayock et al. 2015, Juul and Pet 2015, 70 Natalucci, Latal et al. 2016). EPO signaling, leads to activation of several downstream 71 pathways including the STAT5, ERK1/2 and PI3K/Akt pathways (Lombardero, Kovacs et al. 72 2011). EPO’s immediate neuroprotective effects are anti-apoptotic, anti-inflammatory, and 73 anti-oxidative (Noguchi, Asavaritikrai et al. 2007, Rangarajan and Juul 2014). In the long- 74 term, EPO stimulates angiogenesis (Zhu, Bai et al. 2014), neurogenesis (Castaneda- 75 Arellano, Beas-Zarate et al. 2014) and oligodendrogenesis (Jantzie, Miller et al. 2013, Juul, 76 Mayock et al. 2015). EPO has also been shown to restore deficits in potasium-chloride 77 cotransporter 2 (KCC2) expression (Jantzie, Getsy et al. 2014), and enhance synaptic 78 plasticity and cognition (Adamcio, Sargin et al. 2008, Kamal, Al Shaibani et al. 2011, Sargin, 79 El-Kordi et al. 2011, Almaguer-Melian, Merceron-Martinez et al. 2015), while facilitating 3 80 inhibitory synaptic transmission (Wojtowicz and Mozrzymas 2008, Roseti, Cifelli et al. 2020). 81 Nevertheless, it is not yet established whether EPO promotes the development of GABAergic 82 neurons and GABAergic neurotransmission. 83 EPO and its receptor (EPOR) are expressed in human and mouse brain (Digicaylioglu, 84 Bichet et al. 1995, Marti, Wenger et al. 1996). Specifically, they are reported to be expressed 85 in the embryonic neocortex in areas close to ventricles and deeper layers, regulating radial 86 migration and laminar positioning of granular neurons (Constanthin, Contestabile et al. 87 2020). Here we report that EPORs are highly expressed postnatally in the cornu ammonis 88 (CA)1 hippocampus from mice, increasing their expression to reach a zenith towards 89 adulthood. Additionally, we showed in a transgenic mouse line constitutively overexpressing 90 human EPO in the CNS, without hematopoietic changes (Tg21) (Wiessner, Allegrini et al. 91 2001), a strong activation of the AKT pathways in the postnatal CA1 hippocampus (Jacobs 92 R. A. et al, Comm biology, in revision). AKT phosphorylation has a strong antiapoptotic 93 action and can increase the number of GABAARs on the plasma membrane increasing 94 synaptic transmission in neurons (Wang, Liu et al. 2003). Therefore, we hypothesize an 95 important role for EPO signaling in postnatal hippocampal GABAergic maturation. 96 During the second postnatal week, GABAergic transmission in the cornu ammonis (CA) 97 hippocampus switches from excitatory, due to elevated intracellular chloride concentration, to 98 inhibitory at around postnatal days (P)13-15 (Tyzio, Holmes et al. 2007), an age that 99 coincides with a peak in synaptogenesis, and the formation of adult neuronal networks (Ben- 100 Ari, Gaiarsa et al. 2007). GABAergic transmission is essential for establishing critical periods 101 of enhanced synaptic plasticity during development (Hensch and Bilimoria 2012). 102 Perineuronal nets (PNNs) are specialized extracellular matrix (ECM) structures composed of 103 chondroitin sulfate proteoglycans that are responsible for synaptic stabilization, a process 104 that influences the closing of critical periods of plasticity. In the hippocampus PNNs are found 105 around the somata and proximal dendrites
Load more

Recommended publications
  • PDGFB Split FISH Probe Storage Instruction: Store at 4°C in the Dark
    PDGFB Split FISH Probe Storage Instruction: Store at 4°C in the dark. Entrez GeneID: 5155 Catalog Number: FS0009 Gene Symbol: PDGFB Regulatory Status: For research use only (RUO) Gene Alias: FLJ12858, PDGF2, SIS, SSV, c-sis Product Description: Labeled FISH probes for identification of gene split using Fluoresecent In Situ Gene Summary: The protein encoded by this gene is a Hybridization Technique. (Technology) member of the platelet-derived growth factor family. The four members of this family are mitogenic factors for Probe 1: cells of mesenchymal origin and are characterized by a Size: motif of eight cysteines. This gene product can exist Fluorophore: either as a homodimer (PDGF-BB) or as a heterodimer Location: PDGFB(Texas Red) with the platelet-derived growth factor alpha polypeptide Approximately 470kb (PDGF-AB), where the dimers are connected by Texas Red disulfide bonds. Mutations in this gene are associated 22q13.1 with meningioma. Reciprocal translocations between Probe 2: chromosomes 22 and 7, at sites where this gene and Size: that for COL1A1 are located, are associated with a Fluorophore: particular type of skin tumor called dermatofibrosarcoma Location: PDGFB(FITC) protuberans resulting from unregulated expression of Approximately 610kb growth factor. Two alternatively spliced transcript FITC variants encoding different isoforms have been identified 22q13.1 for this gene. [provided by RefSeq] Probe Gap: The gap between two probes is approximately 50 kb Source: Genomic DNA Origin: Human Notice: We strongly recommend the customer to use FFPE FISH PreTreatment Kit 1 (Catalog #: KA2375 or KA2691) for the pretreatment of Formalin-Fixed Paraffin-Embedded (FFPE) tissue sections.
    [Show full text]
  • PDGFB Regulates the Development of the Labyrinthine Layer of the Mouse Fetal Placenta
    Developmental Biology 212, 124–136 (1999) Article ID dbio.1999.9306, available online at http://www.idealibrary.com on PDGFB Regulates the Development of the Labyrinthine Layer of the Mouse Fetal Placenta Rolf Ohlsson,*,1 Pierre Falck,* Mats Hellstro¨m,† Per Lindahl,† Hans Bostro¨m,† Gary Franklin,* Lars A¨ hrlund-Richter,‡ Jeffrey Pollard,§ Philippe Soriano,¶ and Christer Betsholtz† *Department of Animal Development & Genetics, Uppsala University, Norbyva¨gen 18A, S-752 36 Uppsala, Sweden; †Department of Medical Biochemistry, Gothenburg University, Medicinaregatan 9A, S-413 90 Gothenburg, Sweden; ‡Department of Medical Nutrition, Karolinska Institute, Huddinge, Sweden; §Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York 10461; and ¶Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 PDGFB is a growth factor which is vital for the completion of normal prenatal development. In this study, we report the phenotypic analysis of placentas from mouse conceptuses that lack a functional PDGFB or PDGFRb gene. Placentas of both types of mutant exhibit changes in the labyrinthine layer, including dilated embryonic blood vessels and reduced numbers of both pericytes and trophoblasts. These changes are seen from embryonic day (E) 13.5, which coincides with the upregulation of PDGFB mRNA levels in normal placentas. By E17, modifications in shape, size, and number of the fetal blood vessels in the mutant placentas cause an abnormal ratio of the surface areas between the fetal and the maternal blood vessels in the labyrinthine layer. Our data suggest that PDGFB acts locally to contribute to the development of the labyrinthine layer of the fetal placenta and the formation of a proper nutrient–waste exchange system during fetal development.
    [Show full text]
  • Ep 3217179 A1
    (19) TZZ¥ ___T (11) EP 3 217 179 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 13.09.2017 Bulletin 2017/37 G01N 33/68 (2006.01) (21) Application number: 17167637.2 (22) Date of filing: 02.10.2013 (84) Designated Contracting States: • LIU, Xinjun AL AT BE BG CH CY CZ DE DK EE ES FI FR GB San Diego, CA 92130 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • HAUENSTEIN, Scott PL PT RO RS SE SI SK SM TR San Diego, CA 92130 (US) • KIRKLAND, Richard (30) Priority: 05.10.2012 US 201261710491 P San Diego, CA 92111 (US) 17.05.2013 US 201361824959 P (74) Representative: Krishnan, Sri (62) Document number(s) of the earlier application(s) in Nestec S.A. accordance with Art. 76 EPC: Centre de Recherche Nestlé 13779638.9 / 2 904 405 Vers-chez-les-Blanc Case Postale 44 (71) Applicant: Nestec S.A. 1000 Lausanne 26 (CH) 1800 Vevey (CH) Remarks: (72) Inventors: This application was filed on 21-04-2017 as a • SINGH, Sharat divisional application to the application mentioned Rancho Santa Fe, CA 92127 (US) under INID code 62. (54) METHODS FOR PREDICTING AND MONITORING MUCOSAL HEALING (57) The present invention provides methods for pre- an individual with a disease such as IBD. Information on dicting the likelihood of mucosal healing in an individual mucosal healing status derived from the use of the with a disease such as inflammatory bowel disease present invention can also aid in optimizing therapy (IBD).
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • PDGFB-Based Stem Cell Gene Therapy Increases Bone Strength in the Mouse
    PDGFB-based stem cell gene therapy increases bone PNAS PLUS strength in the mouse Wanqiu Chena, David J. Baylinka, Justin Brier-Jonesa, Amanda Neisesa, Jason B. Kiroyana, Charles H. Rundlea,b, Kin-Hing William Laua,b, and Xiao-Bing Zhanga,1 aDepartment of Medicine, Loma Linda University, Loma Linda, CA 92354; and bMusculoskeletal Disease Center, Jerry L. Pettis Memorial VA Medical Center, Loma Linda, CA 92357 Edited by David W. Russell, University of Texas Southwestern Medical Center, Dallas, TX, and approved June 5, 2015 (received for review January 27, 2015) Substantial advances have been made in the past two decades in (HSC) cell therapy, which could be given intravenously and would the management of osteoporosis. However, none of the current result in rejuvenation of the skeleton (9). We have shown en- medications can eliminate the risk of fracture and rejuvenate the graftment of donor HSCs that were genetically engineered to skeleton. To this end, we recently reported that transplantation overexpress FGF2 at sites where bone is lost in osteoporosis (i.e., + of hematopoietic stem/progenitor cells (HSCs) or Sca1 cells engi- the HSC niches), which in turn resulted in substantial augmenta- neered to overexpress FGF2 results in a significant increase in la- tion of bone matrix formation at these sites (9). Despite these mellar bone matrix formation at the endosteum; but this increase advances, we encountered several issues that severely compro- was attended by the development of secondary hyperparathyroid- mised the efficacy of our therapy. Instead of being stronger, the ism and severe osteomalacia. Here we switch the therapeutic gene resulting bones were actually weaker and sometimes fractured PDGFB to , another potent mitogen for mesenchymal stem cells during tissue processing.
    [Show full text]
  • Melanoma Antibodies
    Melanoma Antibodies Catalog No. Product Name Applications Reactivity H00000207-M03 AKT1 monoclonal antibody (M03) WB, IHC, IF, ELISA, IP Human, Mouse, Rat H00000208-M01 AKT2 monoclonal antibody (M01) WB, IF, ELISA Human H00010000-M02 AKT3 monoclonal antibody (M02) WB, IF, ELISA Human H00000369-M05 ARAF monoclonal antibody (M05) WB, ELISA, PLA Human H00000572-M02 BAD monoclonal antibody (M02) WB, ELISA, PLA Human H00000673-M01A BRAF monoclonal antibody (M01A) WB, ELISA Human MAB15125 CCND1 monoclonal antibody WB, IHC Human H00000999-M01 CDH1 monoclonal antibody (M01) WB, IHC, ELISA, PLA Human H00001019-M03 CDK4 monoclonal antibody (M03) WB, IF, ELISA, RNAi Human H00001021-M01 CDK6 monoclonal antibody (M01) WB, IHC, IF, ELISA, PLA Human, Rat H00001026-M02 CDKN1A monoclonal antibody (M02) WB, IHC, IF, ELISA, PLA Human H00001029-M06 CDKN2A monoclonal antibody (M06) WB, IF, ELISA Human MAB6761 E2F1 (phospho S364) monoclonal antibody WB, IP, ELISA Human PAB26868 E2F2 polyclonal antibody WB, IHC Human, Mouse H00001871-M01 E2F3 monoclonal antibody (M01) WB, ELISA, PLA Human MAB10630 EGF monoclonal antibody WB, IHC, ELISA Human H00001956-M02 EGFR monoclonal antibody (M02) ELISA Human H00002246-M02 FGF1 monoclonal antibody (M02) WB, IHC, IF, IP, ELISA Human MAB5421 FGF2 monoclonal antibody WB, ELISA Human MAB7094 FGF3 monoclonal antibody WB, IHC, IF Human, Mouse, Xenopus PAB4025 FGF4 polyclonal antibody WB, IHC, ELISA Human Melanoma Antibodies Melanoma PAB28140 FGF7 polyclonal antibody IHC Human H00002253-M01 FGF8 monoclonal antibody (M01) WB,
    [Show full text]
  • Detection of COL1A1-PDGFB Fusion Transcripts and PDGFB/PDGFRB Mrna Expression in Dermatofibrosarcoma Protuberans
    Modern Pathology (2007) 20, 668–675 & 2007 USCAP, Inc All rights reserved 0893-3952/07 $30.00 www.modernpathology.org Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans Tomonari Takahira1, Yoshinao Oda1, Sadafumi Tamiya1, Koichi Higaki2, Hidetaka Yamamoto1, Chikashi Kobayashi1, Teiyu Izumi1, Naomi Tateishi1, Yukihide Iwamoto3 and Masazumi Tsuneyoshi1 1The Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 2Department of Pathology, Saint Mary’s Hospital, Kurume, Japan and 3Department of Orthopedic Surgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Fusion of the collagen type I alpha 1 (COL1A1) gene with the platelet-derived growth factor beta chain (PDGFB) gene has been described in dermatofibrosarcoma protuberans. The abnormal fusion transcripts probably cause PDGFB and its receptor (platelet-derived growth factor receptor beta, PDGFRB) autocrine stimulation and cell proliferation, which are responsible for the development of dermatofibrosarcoma protuberans. A reverse transcription–polymerase chain reaction assay was performed to detect the COL1A1-PDGFB fusion transcripts in 57 samples. In addition, the PDGFB gene amplification and PDGFB/PDGFRB mRNA levels were quantified by a real-time PCR system for the samples in which the fusion transcripts had been successfully detected. The fusion transcripts were detected in 42 of 57 samples. Various exons of the COL1A1 gene were fused in frame with the PDGFB gene; exons 7 and 25 were found to be slightly more frequently involved than the other exons. The PDGFB gene amplification levels varied from 0.6 to 8.3 (mean 2.4) in 42 tumor samples and from 0.4 to 3.0 (mean 1.2) in 20 adjacent normal tissue samples.
    [Show full text]
  • The Transcriptional Coactivator TAZ Regulates Mesenchymal Differentiation in Malignant Glioma
    Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma Krishna P.L. Bhat,1,6,11 Katrina L. Salazar,1,6 Veerakumar Balasubramaniyan,2,5,6 Khalida Wani,1 Lindsey Heathcock,1 Faith Hollingsworth,1 Johanna D. James,1 Joy Gumin,3 Kristin L. Diefes,1 Se Hoon Kim,1,7 Alice Turski,1 Yasaman Azodi,1 Yuhui Yang,3 Tiffany Doucette,3 Howard Colman,2,8,9 Erik P. Sulman,4 Frederick F. Lang,3 Ganesh Rao,3 Sjef Copray,5 Brian D. Vaillant,2,10 and Kenneth D. Aldape1 1Department of Pathology, 2Department of Neuro-Oncology, 3Department of Neurosurgery, 4Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA; 5Department of Neuroscience, University Medical Center Groningen, 9713 AV Groningen, The Netherlands Recent molecular classification of glioblastoma (GBM) has shown that patients with a mesenchymal (MES) gene expression signature exhibit poor overall survival and treatment resistance. Using regulatory network analysis of available expression microarray data sets of GBM, including The Cancer Genome Atlas (TCGA), we identified the transcriptional coactivator with PDZ-binding motif (TAZ ), to be highly associated with the MES network. TAZ expression was lower in proneural (PN) GBMs and lower-grade gliomas, which correlated with CpG island hypermethylation of the TAZ promoter compared with MES GBMs. Silencing of TAZ in MES glioma stem cells (GSCs) decreased expression of MES markers, invasion, self-renewal, and tumor formation. Conversely, over- expression of TAZ in PN GSCs as well as murine neural stem cells (NSCs) induced MES marker expression and aberrant osteoblastic and chondrocytic differentiation in a TEAD-dependent fashion.
    [Show full text]
  • WO 2014/054013 Al 10 April 2014 (10.04.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/054013 Al 10 April 2014 (10.04.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every G01N 33/68 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/IB2013/059077 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, 2 October 2013 (02. 10.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/710,491 5 October 2012 (05. 10.2012) 61/824,959 17 May 2013 (17.05.2013) (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: NESTEC S.A. [CH/CH]; Ave. Nestle 55, CH- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 1800 Vevey (CH).
    [Show full text]
  • Srfdependent Gene Expression Is Required for Pi3kinaseregulated Cell
    The EMBO Journal Vol. 19 No. 18 pp. 4955±4966, 2000 SRF-dependent gene expression is required for PI3-kinase-regulated cell proliferation Steve Poser, Soren Impey, Kien Trinh, embryonic lethality. The identi®cation of oncogenic forms Zhengui Xia1 and Daniel R.Storm2 of p110 and p85 PI3K further illustrates the critical role of PI3K in proliferation (Chang et al., 1997; Jimenez et al., Department of Pharmacology, School of Medicine, University of Washington and 1Department of Environmental Health and 1998). Toxicology, School of Environmental Health, University of The identi®cation of the tumor suppressor, PTEN, as a Washington, Seattle, WA98195, USA D3 phosphoinositide phosphatase underscores the critical 2Corresponding author role of PI3K in cell growth and oncogenesis (Myers et al., e-mail: [email protected] 1998). Asigni®cant fraction of human cancers contain deletions or mutations of PTEN (for review see Cantley S.Poser and S.Impey contributed equally to this work and Neel, 1999). However, the mechanisms by which PTEN regulates cell cycle progression are not clear and the Recent evidence indicates that phosphatidylinositol targets of PI3K signaling during mitosis remain obscure. 3-kinase (PI3K) is a central regulator of mitosis, apop- The ability of mitogens to trigger cell cycle progression tosis and oncogenesis. Nevertheless, the mechanisms depends on the rapid transcription of immediate early by which PI3K regulates proliferation are not well genes (IEGs). In particular, c-fos and related transcription characterized. Mitogens stimulate entry into the cell factors play a critical role in mitogenesis (Riabowol et al., cycle by inducing the expression of immediate early 1988; Kovary and Bravo, 1991) by inducing the expres- genes (IEGs) that in turn trigger the expression sion of genes necessary for the activation of G cyclins of G cyclins.
    [Show full text]
  • Platelet Derived Growth Factor-B and Human Epidermal Growth Factor Receptor-2 Polymorphisms and Gall Bladder Cancer
    DOI:http://dx.doi.org/10.7314/APJCP.2015.16.14.5647 Platelet Derived Growth Factor-B and Human Epidermal Growth Factor Receptor-2 Polymorphisms and Gall Bladder Cancer RESEARCH ARTICLE Platelet Derived Growth Factor-B and Human Epidermal Growth Factor Receptor-2 Polymorphisms in Gall Bladder Cancer Kumudesh Mishra1,2, Anu Behari1, Vinay Kumar Kapoor1, M. Salman Khan2, Swayam Prakash3, Suraksha Agrawal3* Abstract Gall bladder cancer (GBC) is a gastro-intestinal cancer with high prevalence among north Indian women. Platelet derived growth factor-B (PDGFB) and human epidermal growth factor receptor-2 (HER2) may play roles in the etiology of GBC through the inflammation-hyperplasia-dysplasia-carcinoma pathway. To study the association of PDGFB and HER2 polymorphisms with risk of GBC, 200 cases and 300 controls were considered. PDGFB +286A>G and +1135A>C polymorphisms were investigated with an amplification refractory mutation system and the HER2 Ile655Val polymorphism by restriction fragment length polymorphism. Significant risk associations for PDGFB +286 GG (OR=5.25) and PDGFB +1135 CC (OR=3.19) genotypes were observed for GBC. Gender wise stratification revealed susceptibility for recessive models ofPDGFB +1135A>C (OR=3.00) and HER2 Ile655Val (OR=2.52) polymorphisms among female GBC cases. GBC cases with gall stones were predisposed to homozygous +286 GG and +1135 CC genotypes. Significant risk associations were found for ACIle (OR=1.48), GAVal (OR=1.70), GAIle (OR=2.00) haplotypes with GBC cases and GCIle haplotype with female GBC cases (OR=10.37, P=<0.0001). Pair-wise linkage disequilibrium revealed negative associations among variant alleles.
    [Show full text]
  • Feedback Regulation of RTK Signaling in Development ⁎ Cynthia L
    Developmental Biology xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Developmental Biology journal homepage: www.elsevier.com/locate/developmentalbiology Review article Feedback regulation of RTK signaling in development ⁎ Cynthia L. Nebena, Megan Loa,b, Natalia Jurab,c, , Ophir D. Kleina,d,⁎⁎ a Department of Orofacial Sciences and Program in Craniofacial Biology, University of California, San Francisco, San Francisco 94143, USA b Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, USA c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA d Department of Pediatrics and Institute for Human Genetics, University of California, San Francisco, San Francisco 94143, USA ARTICLE INFO ABSTRACT Keywords: Precise regulation of the amplitude and duration of receptor tyrosine kinase (RTK) signaling is critical for the Receptor tyrosine kinases execution of cellular programs and behaviors. Understanding these control mechanisms has important Signaling pathways implications for the field of developmental biology, and in recent years, the question of how augmentation or Feedback regulation attenuation of RTK signaling via feedback loops modulates development has become of increasing interest. RTK Developmental control feedback regulation is also important for human disease research; for example, germline mutations in genes RASopathies that encode RTK signaling pathway components cause numerous human congenital syndromes, and somatic Sprouty alterations contribute to the pathogenesis of diseases such as cancers. In this review, we survey regulators of RTK signaling that tune receptor activity and intracellular transduction cascades, with a focus on the roles of these genes in the developing embryo. We detail the diverse inhibitory mechanisms utilized by negative feedback regulators that, when lost or perturbed, lead to aberrant increases in RTK signaling.
    [Show full text]